# TCMD earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TCMD) · [Earnings tab](https://www.lopjlb.com/stock/TCMD?tab=earnings)

Updated: 2026-08-10T05:24:34

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings calls, TCMD moved from modest growth tempered by tightening Medicare documentation to a phase of accelerating revenue and margin expansion. In Q2 2024 the company posted 7% revenue growth but cut full‑year guidance as Medicare MACs tightened documentation and the PHE waiver expired, creating headwinds for Airway Clearance sales. By Q3 2024 the guidance was further lowered, yet gross margins rose 410 bps to ~74% thanks to lower material costs and warranty reductions. The Q4 2024 call introduced the Nimbl launch and highlighted the retirement of the LCD policy, signaling a regulatory tailwind. FY2025 guidance turned positive, projecting 8‑10% growth, while the 2025‑2026 period saw consistent double‑digit revenue growth, strong demand across VA, commercial and Medicare channels, and expanding sales force. Margin improvement continued with AI‑driven back‑office efficiencies and lower manufacturing costs. Strategic milestones accelerated: e‑prescribing and CRM tools moved from rollout to full implementation, the Nimbl product launched, and the LymphaTech acquisition was announced and entered integration. New reimbursement challenges emerged in 2026 with Medicare prior‑authorization requirements, adding short‑term headwinds, while integration and regulatory risks around next‑gen AffloVest surfaced. Overall, the narrative shifts from early documentation constraints to robust commercial execution tempered by evolving reimbursement and integration risks.

## Latest CallCard · Q1

TCMD reports strong Q1 2026: $75.3M revenue (+23% YoY), gross margin 76.5% (+250bps), adj. EBITDA $3.7M; raises FY26 guidance to $360-368M; accelerates prior auth AI module; integrates Lymphotech acquisition.

**Guidance:** raised — Full-year 2026 revenue guidance updated to $360-368M, reflecting Lymphotech inclusion and increased confidence in commercial execution while maintaining discipline on prior authorization maturation.

**Tone:** mgmt 0.5 · Q&A pressure 0.3 · divergence 0.2

Prepared remarks emphasize strong execution, margin expansion, strategic progress, and confidence in commercial plan despite prior authorization transition.

### Demand visibility

Underlying demand healthy across channels; Medicare ordering patterns may normalize as prior authorization settles; commercial consistent; VA stable but slower growth profile.

Management states underlying demand remains healthy and expects quarterly ordering patterns to normalize as new prior authorization process settles. Commercial business shows quarter-over-quarter consistency. VA channel has stable reimbursement but different growth profile, expected to become more meaningful over time. Medicare channel grew 40% YoY partly due to order acceleration ahead of April 13 prior auth effective date.

### Margins / costs

Gross margin expanded 250bps to 76.5%; adj. EBITDA up $4M YoY; AI-driven back-office efficiencies expected to support further margin expansion.

Q1 gross margin increased 250 basis points to 76.5%. Adjusted EBITDA increased $4 million year over year to $3.7 million. AI-enabled technology in order intake, medical record review, and newly launched prior authorization module are driving workflow efficiencies. Further AI expansion across eligibility verification and full medical record review expected to accelerate speed of therapy, reduce errors, and improve operational efficiency, supporting margin expansion over time.

### Capital allocation

Maintains $75M cash for financial flexibility; investing in long-term growth via Lymphotech acquisition and AI platform; no buybacks or dividends mentioned.

Ended Q1 with approximately $75 million in cash, maintaining substantial financial flexibility while continuing to invest for long-term growth. Capital deployed for Lymphotech acquisition (closed February) and accelerated development of AI prior authorization module. Focus on strategic investments in technology, commercial expansion, and R&D capabilities.

### Milestones

- **Lymphotech acquisition integration** [on_track]: Integration progressing as planned since February close; cofounders contributing to go-to-market strategy and product roadmap integration.
- **Medicare prior authorization AI module launch** [delivered]: Accelerated from original 2027 plan; successfully validated, trained staff, and deployed on schedule for April 13 effective date.
- **Next-generation AffloVest product launch** [on_track]: Planned for respiratory season end of 2026 into 2027; training and education aligned with Gen 5 inventory wind-down.
- **AI platform expansion across order process** [on_track]: Expanding AI capabilities to patient eligibility, benefits verification, and full medical record review.
- **Clinical guidelines dissemination for lower extremity lymphedema** [on_track]: Guidelines presented at AVS February 2026, publication expected summer 2026; team prepared for clinician education rollout.
- **Head and neck lymphedema coverage expansion** [on_track]: Clinical evidence program advancing through peer review; working to align commercial payer policies to NCD.
- **GUIDE program research (bioimpedance responsive garment)** [new]: Lymphotech selected as one of seven GUIDE awardees under ARPA-H; developing adaptive compression garment with remote monitoring.
- **NCD alignment for Flexitouch advanced pump documentation** [delivered]: Aligned documentation criteria with Medicare NCD in October 2025; driving favorable product mix and 40% Medicare channel growth.

### Fears / risks

- **Medicare prior authorization transition**: New prior authorization requirements for fee-for-service Medicare patients effective April 13 add documentation steps, face-to-face visit requirement, and MAC process adjustments; early transition dynamics may disrupt ordering patterns.
- **MAC process uncertainty**: Both company and Medicare Administrative Contractors are adjusting processes; outcomes under new requirements continue to mature.
- **Order pattern normalization risk**: Q1 Medicare growth included order acceleration ahead of April 13 deadline; quarterly patterns may fluctuate as new process settles.
- **Lymphotech integration execution**: Integration of technology, team, and product roadmaps carries execution risk; maximizing provider/clinician/patient experience requires deliberate approach.
- **Commercial payer policy alignment**: Some commercial policies still aligned to retired LCD rather than NCD; aligning policies requires ongoing payer engagement and clinical evidence.
- **VA channel growth profile**: VA reimbursement stable but growth unfolds deliberately; diverse call points and local system navigation may slow contribution.
- **Bronchiectasis pharmaceutical competition**: New pharmaceutical product for bronchiectasis may alter care pathways; management believes it complements rather than replaces airway clearance but monitors impact.
- **Reimbursement policy volatility**: Dependence on Medicare NCD, LCD retirement, and commercial payer policies creates ongoing regulatory and reimbursement risk.

### Key quotes

> “We are pleased to report a strong start to 2026, with first quarter results reflecting focused execution of our three strategic priorities, continued strength and durability of our commercial action plan, and operational excellence”

> “For 2026, we are updating our full-year revenue guidance to a range of $360 million to $368 million. This update reflects the inclusion of Lymphotech and our increased confidence in commercial execution while maintaining a disciplined”

> “The Medicare PCD prior authorization requirement has been in place for just three weeks. We are actively managing early transition dynamics as both we and the MACs adjust our respective processes.”

> “We have said and believe that the introduction of the pharmaceutical product specifically for patients with bronchiectasis is helping awareness for the broader category, so it has been a nice category lift. The airway clearance, though—and” — Sheri Louise Dodd

> “I think it is accurate that the lower extremity is the larger population. I think what Sheri is highlighting is that the guidelines are more meaningful for that population because there is not an obvious trigger to the lymphatic” — Elaine M. Birkemeyer

## Quarter one-liners

- **2026 Q1:** TCMD reports strong Q1 2026: $75.3M revenue (+23% YoY), gross margin 76.5% (+250bps), adj. EBITDA $3.7M; raises FY26 guidance to $360-368M; accelerates prior auth AI module; integrates Lymphotech acquisition.
- **2025 Q4:** Tactile Medical posted strong Q4 revenue and margin growth, announced a LymphaTech acquisition, and guided 2026 revenue $357‑$365M while noting a short‑term Medicare prior‑auth headwind.
- **2025 Q3:** TCMD delivered strong Q3 with revenue $85.8M (+17% YoY), lymphedema +11%, airway clearance +71%; raised FY25 revenue guidance to $317-321M (8-10% growth) and adj. EBITDA to $38-39.5M; launched $25M share buyback; advancing strategic priorities including NCD tailwind, next-gen AffloVest 510(k), AI or
- **2025 Q2:** TCMD Q2 2025: Revenue $78.9M (+7.8% YoY), lymphedema +2%, airway clearance +52%; gross margin 74.5% (+60bps); adj. EBITDA $7.7M (-15%); guidance raised to $310-315M (6-8% growth), adj. EBITDA $33-35M; CRM disruption behind, sales force expanding to 300+ reps; Nimbl adoption strong, AffloVest partner
- **2025 Q1:** TCMD Q1 revenue $61.3M (+0.3% YoY); lymphedema -3% to $50.6M, airway clearance +22% to $10.7M. Gross margin +290bps, adj. EBITDA -125% due to CRM/sales tech investments. Guidance revised: Q2 $73-76M, FY $309-315M. Sales force optimization and CRM launch causing transient headwinds; hiring to 300 rep
- **2024 Q4:** TCMD reports Q4 revenue $85.6M (+10.2% YoY), FY2024 $293M (+6.8%), guides FY2025 $316-322M (8-10% growth); highlights Nimbl launch, LCD retirement, head/neck RCT, and three strategic priorities for 2025.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management emphasizes strong commercial execution, dou
- **2024 Q3:** TCMD Q3 revenue $73.1M (+5% YoY), EBITDA +39%, but revenue guidance lowered to $292-295M due to Medicare documentation headwinds; CMS retiring LCD policy Nov 14 seen as positive for patient access. Gross margin expanded 410 bps to ~74%.
- **2024 Q2:** TCMD delivered 7% revenue growth and a 49% jump in adjusted EBITDA in Q2, raised cash to $73.6M, but revised full‑year revenue guidance lower amid tougher Medicare documentation and a modest headwind from the PHE waiver expiration.

## Theme arcs

- **Revenue growth** (improving): From modest 5‑7% YoY growth in 2024 to 17% YoY in Q3 2025 and 23% YoY in Q1 2026.
- **Guidance trajectory** (stable): Initial guidance cuts in 2024 gave way to positive FY2025 guidance and raised FY2026 targets.
- **Margin expansion** (improving): Gross margin rose from ~74% in Q3 2024 to 76.5% in Q1 2026, aided by lower costs and AI efficiencies.
- **Medicare documentation/reimbursement** (deteriorating): Persistent MAC tightening in 2024 evolved into prior‑authorization headwinds in 2026.
- **Technology investment** (new): CRM, e‑prescribing, AI platform and Nimbl product introduced and scaled.
- **Sales force expansion** (improving): Hiring to >300 reps and optimization improved coverage despite short‑term productivity dips.
- **Product pipeline** (improving): Nimbl launch, next‑gen AffloVest progress, and LymphaTech acquisition expanded offerings.
- **DME buying volatility** (resolved): Early uneven DME ordering noted in 2024, not referenced in later calls.
- **Regulatory risk (510k)** (new): AffloVest 510(k) submission risk surfaced in 2026.
- **Competitive landscape** (new): Competitive risk in airway clearance highlighted in 2026.

## Guidance path

2024 Q2:lowered → 2024 Q3:lowered → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TCMD`